Mindeudesivir

• CAT Number: S000537
• CAS Number: 2647442-33-7
• Molecular Formula: C24H30DN5O7
• Molecular Weight: 502.54
• Purity: ≥95%
• IUPAC Name: [(2R,3R,4R,5R)-5-(4-amino-5-deuteriopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-bis(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate
• InChI: InChI=1S/C24H31N5O7/c1-12(2)21(30)33-9-16-18(34-22(31)13(3)4)19(35-23(32)14(5)6)24(10-25,36-16)17-8-7-15-20(26)27-11-28-29(15)17/h7-8,11-14,16,18-19H,9H2,1-6H3,(H2,26,27,28)/t16-,18-,19-,24+/m1/s1/i7D
• InChIKey: RVSSLHFYCSUAHY-QXMJNOOVSA-N
• SMILES: CC(C)C(=O)OCC1C(C(C(O1)(C#N)C2=CC=C3N2N=CN=C3N)OC(=O)C(C)C)OC(=O)C(C)C

Mindeudesivir（Cat No.:S000537）is an investigational antiviral drug designed to inhibit the replication of RNA viruses, including coronaviruses like SARS-CoV-2. It is a nucleotide analog that targets the viral RNA-dependent RNA polymerase (RdRp), a key enzyme in the viral replication cycle. By interfering with this enzyme, Mindeudesivir disrupts viral RNA synthesis, preventing the virus from replicating within host cells. This drug is being studied for its potential use in treating viral infections, particularly COVID-19 and other RNA virus-related diseases. Mindeudesivir is currently in clinical trials to evaluate its safety, efficacy, and therapeutic potential.